Herantis Pharma

Herantis Pharma Plc, Press Release, 6 April 2023 at 09:00 A.M. EEST

Herantis Pharma Plc ("Herantis"), developing disease-modifying therapies for Parkinson's disease, today announced the participation in Nordic Health Summit Japan, April 25^th, 2023.

About Nordic Health Summit Japan:

The Nordic Health Summit Japan is a partnering and investor conference that connects Nordic healthcare innovations and Japanese investors and industry, organized by Business Sweden.

If you want to learn more about Herantis and our asset HER-096, you can contact the conference organizers or connect with us directly at ir@herantis.com.

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson's disease. Herantis' lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Company website: www.herantis.com